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Background: Increased sodium uptake has been shown to contribute to hypertension and cardiac end-
organ damage. The sodium-proton-exchanger subtype 3 (NHE3) is an important mediator of intestinal
sodium absorption. Whether a reduction in intestinal sodium absorption can prevent the development
of an atrial arrhythmogenic substrate in hypertension is unknown.
Methods: Eight-week-old obese spontaneously hypertensive rats (SHR-ob) were treated for six weeks
with the gut-specific NHE3-inhibitor SAR (1-(b-D-glucopyranosyl)-3-{3-[(4S)-6,8-dichloro-2-methyl-1,
2,3,4-tetrahydroiso-chinolin-4-yl]phenyl}urea, 1 mg/kg/d in chow, SHR-ob SAR, n = 7) and compared
to aged-matched placebo-treated SHR-ob (SHR-ob PLAC, n = 8). Cardiac magnetic resonance imaging
was performed at the end of the treatment period to assess atrial emptying function. Afterwards, local
conduction disturbances and inducible atrial fibrillation (AF) duration were determined and histological
analysis to quantify atrial fibrosis amount were performed.
Results: Inhibition of intestinal NHE3 by SAR increased fecal sodium excretion, resulted in marked
changes in feces electrolyte concentrations and water content, reduced blood pressure and preserved
atrial emptying function (active total percent emptying: SHR-ob SAR: 0.47 ± 0.05% vs. SHR-ob PLAC: 0.
38 ± 0.007, p < 0.0001). Atrial fibrosis content was lower (21.4 ± 2.5% vs. 36.7 ± 1.2%, p < 0.0001) and areas
of slow conduction were smaller (2.5 ± 0.09% vs. 5.3 ± 0.2%, p < 0.0001) in SHR-ob SAR compared to SHR-
ob PLAC. Left atrial burst stimulation resulted in shorter inducible AF-durations in SHR-ob SAR compared
to SHR-ob PLAC.
Conclusions: Reduction of intestinal sodium absorption and subsequent changes in feces milieu by phar-
macological NHE3 inhibition in the gut preserved atrial emptying function and reduced AF susceptibility.
Whether pharmacological NHE3 inhibition in the gut prevents AF in humans warrants further study.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A Western lifestyle with high salt consumption can lead to
hypertension [1,2] and may contribute to cardiac end-organ dam-
age involving diastolic dysfunction and atrial fibrillation (AF). The
World Health Organization technical report recommends a maxi-mum daily intake of 5–6 g of salt for the general population [3].
Accordingly, salt restriction is also recommended in hypertension
and heart failure guidelines of the European Society of Cardiology
[4,5] but is not mentioned in the current AF guidelines [6].
It is notoriously difficult to sufficiently reduce salt in the human
diet. When determining the relative contributions of dietary salt
sources, salt added during food processing contributes 77% of total
intake, 11.6% was derived from salt inherent to food, and water
was a trivial source [7]. Theoretically, pharmacological modifica-
tion of intestinal sodium absorption may represent an interesting
way of pharmacological reduction of salt intake. Dietary salt is
absorbed in the gastrointestinal tract. Intestinal salt and water
2 B. Linz et al. / IJC Heart & Vasculature 28 (2020) 100534absorption in the gut is mainly regulated by the sodium proton
exchanger subtype 3 (NHE3 also known as Slc9a3), which is highly
expressed at the apical membrane of the intestine and colon [8,9].
Intestinal NHE3 may represent an interesting target for pharmaco-
logical intervention and may help to accomplish a truly low-salt
intake from the gut. Pharmacological inhibition of the intestinal
NHE3 has been shown to reduce intestinal sodium and water
absorption and to result in reduction of blood pressure in hyper-
tensive rat models [9,10] and attenuated progression of hyperten-
sive renal and ventricular end-organ damage [11]. Theoretically,
pharmacological NHE3 inhibition in the gut, initiated at a time
when hypertension, metabolic syndrome and nephropathy are
already fully established, may also prevent the progression of atrial
arrhythmic substrates, which has not been investigated yet.
This study sought to delineate the effects of pharmacological
inhibition of intestinal sodium absorption on development of an
arrhythmogenic substrate for AF in obese spontaneously hyperten-
sive rats (SHR-ob), which carry an additional mutation in the leptin
receptor and express multiple abnormal phenotypes including
hypertension, hyperinsulinemia and metabolic syndrome
[9,11–15]. These rats show a blood pressure approximately corre-
sponding to human hypertension and develop a progressive arrhyth-
mogenic substrate for AF [12]. Whether NHE3 inhibition prevents the
development of an atrial arrhythmic substrate is unclear.2. Materials and methods
Animal experiments were conducted in accordance with the
National Instructions of Health (NIH) Guide for the Care and Use
of Laboratory Animals and with the Welfare guidelines and the
German law for the protection of animals. The experimental proto-
col was reviewed and approved by the responsible institutional
review committee, Darmstadt, Germany.
SAR (Sanofi Aventis Research: 1-(b-D-glucopyranosyl)-3-{3-[(4
S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroiso-chinolin-4-yl]ph
enyl}urea; molecular weight of 512.4 (free base)) is a novel NHE3
inhibitor with very low permeability and an oral bioavailability of
<1%. An oral dose of 1 mg/kg corresponds with a plasma concentra-
tion of about 1 nmol/L. A dose-dependent inhibition study demon-
strated a highly potent IC50 value of 22 nmol/L on rat NHE3 [9].
2.1. Animals
Male obese spontaneously hypertensive rats (SHR-ob, n = 15)
were purchased from Charles River Germany GmbH (Sulzfeld, Ger-
many). The animals were housed individually in standard cages
and received standard chow diet (standard diet #1320, Altromin,
Lage, Germany) and tap water ad libitum. At the age of eight
weeks, rats were randomized into two groups. One group was trea-
ted for six weeks with the NHE3-inhibitor SAR (1 mg/kg/d in stan-
dard chow #1320, Altromin, Lage, Germany) (SHR-ob SAR, n = 7),
the second group served as an untreated control fed with standard
chow only (SHR-ob PLAC, n = 8).
For the determination of urinary and feces sodium-excretion,
the rats were placed over 24 h in metabolic cages (Tecniplast S.p.
a., Buguggiate, Italy) and the urine and feces were sampled. Ion
concentrations in feces were measured (Hitachi 912 analyzer)
and via flame photometry [8]. Water content in the feces was mea-
sured by the Karl Fischer method [8].
2.2. Magnetic resonance imaging
At the age of 14 weeks, rats were anesthetized with 1.5–2.5%
isoflurane and cardiac LA-function was assessed by cardiac mag-
netic resonance imaging (MRI). All scans were acquired with a 7-Downloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissioT magnetic resonance imaging scanner (Bio Spec 70/30; Bruker
Biospin GmbH, Ettlingen, Germany). Multi-slice short-axis cine
imaging was performed from the upper left atrial roof to the apex
with a slice thickness of 1.2 mm and an inter-slice gap of 0 mm.
Orthogonal long axis cine imaging of the LA was acquired. LA
boundaries were obtained in each short-axis image. The LA-
volumes were then determined by Simpson’s rule. LA-area was
manually encircled. The point of insertion of the mitral valve leaf-
lets was taken as the atrioventricular border. Pulmonary veins
were excluded at their ostia and the left atrial appendage was
excluded at its base. All dimensions were measured throughout
the cardiac cycle. The cardiac cycle was divided into 10 equal
phases with an interphase time difference of the spontaneous cycle
length / 10. The MRI-images of all LAs were analyzed by the same
investigator blinded to animal groupings. Representative MRI
images of the left atrium and a further description of the methods
is summarized in [12].
Minimal LA- (LAmin) and maximal LA-volume (LAmax) and
their difference (cyclical change volume) were determined from
the LA-volume/time curves. The minimal volume at the end of
rapid passive emptying (LAre) and the volume before active emp-
tying (LApc) were determined from the volume-time curves as
described elsewhere [16,17]. LA-emptying function parameters
(total percent emptying (LAmax-LAmin)/LAmax)), active percent
emptying ((LApc-LAmin)/LApc), passive percent emptying
(LAmax-LAre)/LAmax)) were computed [12]. LA-volume/body
weight ratio (LA-volume index) was determined to normalize LA
dimensions.2.3. Electrophysiological studies
At the age of 14 weeks, all animals were anaesthetized with
thiopental (Narcoren, 100 mg/kg i.p., Merial, Hallbergmoos, Ger-
many), intubated and lungs were artificially ventilated. Surface
ECG (lead II) was recorded via subcutaneous needle electrodes. A
custom-made mapping electrode with 4*5 unipolar electrodes
(1.0 mm inter-electrode distance) was placed on the LA free wall
to analyze atrial conduction. Unipolar signals were recorded using
a custom-made channel mapping amplifier (filtering bandwidth
0.1–408 Hz, sampling rate 1.0 kHz, A/D resolution 16bits). Unipolar
pacing was performed from the surface of the left atrium (pulse
width of 1 ms at twice the diastolic threshold, cycle length:
150 ms). Maps from 5 consecutive beats were analyzed. Local acti-
vation times were identified by maximum negative dV/dt in each
unipolar electrogram. Local activation time differences were calcu-
lated between neighboring electrodes (conduction times). Conduc-
tion times of  3 ms (equivalent to conduction velocities  33 cm/
s) were considered as being prolonged. Total-atrial activation time
was defined as the time difference between the right atrial activa-
tion time, visualized by a custom made multiple action potential
(MAP)-catheter (Franz-like electrode) next to the pacing electrode,
and the latest left atrial activation time recorded by the mapping
electrode during right atrial-pacing (cycle length: 150 ms). Atrial
effective refractory period (AERP) was measured at a basic cycle
length of 150 ms at the free wall of the LA. The mean of 3 AERP
measurements was used for analysis. Susceptibility to AF was
tested using repetitive 1 s bursts of stimuli (cycle length: 10 ms).
When atrial electrograms showed a rapid atrial rate, cycle
length < 70 ms and duration > 5 beats, AF was diagnosed. The dura-
tion of the longest of three induced subsequent episodes of AF was
taken as inducible AF duration. After completion of electrophysio-
logical measurements, the animals were sacrificed by quick exci-
sion of the hearts under continued deep anesthesia. The hearts
were quickly excised, the atria carefully removed and transferred
to 4% formaldehyde for subsequent histology.penhagen from ClinicalKey.com by Elsevier on July 09, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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LA was fixed in buffered 4% formaldehyde for 24 h and embed-
ded in paraffin for histological evaluation. Tissue sections of 5 lm
were fixed at 56 C overnight, deparaffinized, rehydrated and
stained with hematoxylin and eosin (H&E) to determine cardiomy-
ocyte diameter as a measure of cardiomyocyte hypertrophy and
myocyte-myocyte distances within bundles as a measure of
enhanced extracellular LA matrix formation and endomysial fibro-
sis formation. Representative images of the H&E staining of the left
atrium and a further description of the methods is summarized in
[12]. To visualize total tissue fibrosis amount, the sections were
stained with Picro-Sirius Red. The percentage of the LA consisting
of interstitial collagen was calculated as the ratio of Picro-Sirius-
Red positively stained area over total LA tissue area, excluding
blood vessels and the epi- and endocardial plane, using ImageJ
1.37a (National Institute of Health, USA). Fibrosis was quantified
on three sections per atrium (6–8 fields per section).2.5. Gene expression analyses
Gene expression analysis was performed in left atrial tissue by
real-time polymerase chain reaction. Total RNA was extracted from
whole left atrium by homogenizing in RLT buffer and by using
RNeasy Mini columns (Qiagen). Genomic DNA impurities were
removed by DNase treatment (DNA Removal Kit, Ambion), and
cDNA was synthesized by reverse transcription (Life Science Tech-
nologies). Quantitative real-time polymerase chain reaction was
performed using Taqman primers on an ABI Prism 7500 Sequence
Detector (Applied Biosystems) and c(t) values obtained by using a
respective software (SDS version 1.9). C(t) values were normalized
to corresponding GAPDH controls. The deltaCt was used for statis-
tical analysis and 2 deltaCt standardized to the control group was
used for data presentation. Probes used to amplify the transcripts
were as follows (purchased by Applied Biosystems): GAPDH
(Rn99999916_s1), Transforming growth factor beta 1 (TGF-b1,
Rn00572010_m1), collagen 1a1 (Col1a1, Rn01463848_m1), con-
nective tissue growth factor (CTGF, Rn01537279_g1).2.6. Statistics
Data are presented as means ± SEM and differences were tested
for significance using an unpaired Student’s t-test. A p-value
of<0.05 was considered statistically significant.3. Results
3.1. Feces milieu and blood pressure
Body weight was not changed by SAR (665 ± 11 g vs. 638 ± 15 g,
n.s.). Water consumption was increased in NHE3 inhibitor–treated
SHR-ob when compared with the placebo-treated SHR-ob (SHR-ob
SAR: 68 ± 4 mL/kg per day vs. SHR-ob PLAC: 53 ± 3 mL/kg per day,
p < 0.05). While sodium intake did not change (SHR-ob SAR: 0.64
± 0.03 g/kg/d vs. SHR-ob PLAC: 0.65 ± 0.03 g/kg/d, n.s.), intestinal
NHE3 inhibition by SAR resulted in increased feces electrolyte con-
centrations (Sodium: SHR-ob SAR: 54.3 ± 3.4 vs. SHR-ob PLAC: 17.
5 ± 1.3 mmol/L, p < 0.01; Potassium: SHR-ob SAR: 29.9 ± 3.7 vs
SHR-ob PLAC: 18.5 ± 1.1 mmol/L, p = 0.06; Calcium: SHR-ob SAR:
18.1 ± 0.9 vs. SHR-ob PLAC: 15.8 ± 2.5 mmol/L, n.s.; Chloride:
SHR-ob SAR: 34 ± 2.6 vs. SHR-ob PLAC: 18.0 ± 0.7 mmol/L,
p < 0.01). Higher feces sodium excretion (SHR-ob SAR: 0.19 ± 0.0
1 g/kg/d vs. SHR-ob PLAC: 0.05 ± 0.01 g/kg/d, p < 0.01) was associ-
ated with an increase in feces water content (SHR-ob SAR:Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. C60.5 ± 0.9% vs. SHR-ob PLAC: 35.0 ± 1.3%, p < 0.01) in SAR treated
SHR-ob animals.
The effects of intestinal NHE3 inhibition on blood pressure and
left ventricular function in SHR-ob animals used in this study have
been measured and published previously [9,11]. SAR significantly
reduced intestinal sodium absorption and increased feces water
content in SHR-ob, which was associated with a reduction of blood
pressure from 222 ± 7 mmHg to 198 ± 2 mmHg (p = 0.0001) and a
reduction in left ventricular end-diastolic pressure, while left ven-
tricular end-systolic volume or left ventricular end-diastolic vol-
ume and ejection fraction were unchanged [9,11].
3.2. Left atrial structural remodeling
Total LA tissue fibrosis was increased in SHR-ob PLAC (36.7 ± 1.
2%) compared to SHR-ob SAR (21.4 ± 2.5%, p < 0.0001; Fig. 1A and
B). Myocyte-myocyte distances within bundles as a measure of
enhanced extracellular LA matrix and endomysial fibrosis forma-
tion was enlarged in SHR-ob PLAC (3.20 ± 0.04 mm) compared to
SHR-ob SAR (2.71 ± 0.06, p < 0.0001; Fig. 1C), while LA myocyte
diameters as a measure of cardiomyocyte hypertrophy, was
unchanged between both groups (SHR-ob PLAC: 18.3 ± 0.6 vs.
SHR-ob SAR: 17.4 ± 0.5 mm, n.s. Fig. 1D). Gene expression of trans-
forming growth factor beta 1 (TGFb1), collagen 1a1 and connective
tissue growth factor (CTGF) were lower in SHR-ob SAR than in SHR-
ob PLAC (Table 1).
3.3. Effect of intestinal NHE3 inhibition on left atrial emptying function
In SHR-ob rats, SAR treatment demonstrated a better global LA-
emptying function, as assessed by improved maximal LA volume
index (SHR-ob SAR: 1.06 ± 0.001 ml/g*kg bodyweight vs. SHR-ob
PLAC: 1.03 ± 0.003 ml/g*kg bodyweight, n.s.; Fig. 2A), total percent
emptying (SHR-ob SAR: 0.47 ± 0.05% vs. SHR-ob PLAC: 0.38 ± 0.007,
p < 0.0001; Fig. 2B) compared to placebo-treated SHR-ob. This
preservation of better LA emptying function in SHR-ob SAR was
mainly due to higher active percent emptying (SHR-ob SAR:
0.33 ± 0.01% vs. SHR-ob PLAC: 0.27 ± 0.01, p = 0.0022; Fig. 2C),
while passive percent emptying was not changed (SHR-ob SAR:
0.21 ± 0.01% vs. SHR-ob PLAC: 0.21 ± 0.01, n.s.; Fig. 2D). Represen-
tative MRI images of 10 equal phases throughout the cardiac cycle
at the level of the aortic valve are presented in Fig. 2E.
3.4. Left atrial electrophysiology
Atrial effective refractory period did not differ between SHR-ob
PLAC and SHR-ob SAR (49.4 ± 0.6 ms vs. 50.1 ± 1.1, n.s.). Short epi-
sodes of AF could be induced by atrial burst stimulation in all SHR-
ob PLAC rats (eight of eight) and all SHR-ob SAR rats (seven of
seven). SAR treatment reduced total atrial activation time (SHR-
ob PLAC: 17.13 ± 0.03 vs. SHR-ob SAR: 16.68 ± 0.04 ms,
p < 0.0001; Fig. 3A) and the percentage of regions with slow con-
duction during rapid pacing (SHR-ob PLAC: 5.3 ± 0.24 vs. SHR-ob
SAR: 2.5 ± 0.09%, p < 0.0001; Fig. 3B) in SHR-ob. The median dura-
tion of inducible AF was shorter in SAR-treated SHR-ob (8.85 ± 1.
86 s) than in SHR-ob PLAC (30.0 ± 6.8 s, p < 0.05; Fig. 3C).4. Discussion
Inhibition of NHE3-mediated intestinal sodium absorption
resulted in changes in feces electrolyte concentration and
increased water content, as well as reduced blood pressure in
SHR-ob rats. This was associated with reduced interstitial fibrosis
formation and reduced gene expression of TGFb1, CTGF and colla-
gen 1a1 in the atrium. As a result of these hemodynamic and atrialhagen from ClinicalKey.com by Elsevier on July 09, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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Fig. 1. Structural remodeling of the left atrium. A) Representative picture of Picro-Sirius red stained left atria. B) Quantification of total atrial tissue fibrosis by Picro-Sirius red
staining. C) Myocyte-myocyte distances within bundles as a measure of enhanced extracellular LA matrix formation and D) atrial myocyte diameter. Male obese
spontaneously hypertensive rats (SHR-ob). Placebo (PLAC). NHE3-inhibitor SAR (SAR). SHR-ob PLAC (n = 8) and SHR-ob SAR (n = 7). All values represented as mean ± SEM. For
statistical analysis an unpaired student’s t-test was performed.
Table 1
Differential Gene Expression of left atrial tissue in SHR-ob PLAC (n = 8) and SHR-ob
SAR (n = 7). Transforming growth factor beta 1 (TGFb1), collagen 1a1 (Col1a1),
connective tissue growth factor (CTGF).
SHR-ob PLAC SHR-ob SAR
Gene expression/
GAPDH
Mean [%of mean SHR-ob
PLAC]
Mean [%of mean SHR-ob
PLAC]
TGFb1 100 79 ± 5*
Col1a1 100 52 ± 12*
CTGF 100 69 ± 9*
* p < 0.01 vs. SHR-ob PLAC.
4 B. Linz et al. / IJC Heart & Vasculature 28 (2020) 100534structural changes, NHE3 inhibitor-treated SHR-ob rats showed
improved LA-emptying function parameters, less local atrial con-
duction disturbances and reduced AF susceptibility.
Total interstitial fibrosis formation was increased in SHR-ob,
associated with enhanced myocyte-myocyte distances within bun-
dles of the LA myocardium. An increase in endomysial fibrosis is
consistent with changes observed in AF-patients and animal mod-
els for AF [16–18]. This extracellular matrix remodeling was asso-
ciated with local conduction disturbances and impairment of LA-
emptying function in SHR-ob rats, which may be a functional con-
sequence of the documented structural atrial changes together
with moderate diastolic ventricular dysfunction in SHR-ob
[12,15]. Intestinal NHE3 inhibition reduced LA structural alter-
ations, which was associated with the preservation of better LADownloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissioemptying function and attenuation of increased AF-inducibility
and maintenance. However, left atrial function and atrial electro-
physiological characteristics previously observed in normotensive
rats or spontaneously hypertensive rats could not be achieved in
SAR treated SHR-ob [12].
Our study of selective pharmacological NHE3 inhibition in the
gut provides important insight into the relevant role of intestinal
sodium absorption for the progression of an arrhythmogenic sub-
strate in the atrium. There are several mechanisms how intestinal
NHE3 inhibition may prevent AF. Previously, we showed that phar-
macological inhibition of intestinal NHE3 using an orally non-
absorbable, specific NHE3-inhibitor increased fecal sodium excre-
tion and water content, while circulating sodium concentrations
were not altered [9]. This was associated with a sustained reduc-
tion in systolic blood pressure, reduced cardiac pre- and afterload
and attenuation of cardiac hypertensive end-organ damage in
hypertensive rats [9,11]. In addition to these hemodynamic
changes, inhibition of NHE3-dependent intestinal sodium absorp-
tion results in increased feces sodium concentration and subse-
quent changes in feces milieu, particularly in the distal ilium and
colon, which may critically impact the composition of gut micro-
biota [19]. High salt intake has been shown to affect the gut micro-
biome in mice, particularly by depleting Lactobacillus murinus
[20]. Treatment of mice with these bacteria prevented salt-
sensitive hypertension by modulating autoimmunity [20].
Although we did not study the microbiome after gut-restricted
NHE3 inhibition, modulation of the intraluminal intestinal milieupenhagen from ClinicalKey.com by Elsevier on July 09, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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Fig. 2. Quantification of global left atrial (LA) emptying function. Left atrial (LA) emptying function was assessed by magnetic resonance imaging (MRI) in SHR-ob PLAC (n = 8)
and SHR-ob SAR (n = 7) rats. Global LA function was assessed by determination of A) maximal LA volume index, B) total percent emptying, C) active percent emptying and D)
passive percent emptying. Male obese spontaneously hypertensive rats (SHR-ob). E) Representative MRI images of 10 equal phases throughout the cardiac cycle at the level of
the aortic valve are presented. Placebo (PLAC). NHE3-inhibitor SAR (SAR). All values represented as mean ± SEM. For statistical analysis an unpaired student’s t-test was
performed.
Fig. 3. Left atrial electrophysiological analysis and duration of burst-induced atrial fibrillation. Quantification of A) total atrial activation time and B) areas of slow conduction.
C) Duration of inducible episodes of atrial fibrillation (AF). Male obese spontaneously hypertensive rats (SHR-ob). Placebo (PLAC). NHE3-inhibitor SAR (SAR). SHR-ob PLAC
(n = 8) and SHR-ob SAR (n = 7). All values represented as mean ± SEM. For statistical analysis an unpaired student’s t-test was performed.
B. Linz et al. / IJC Heart & Vasculature 28 (2020) 100534 5documented in this study might be a promising approach to influ-
ence the composition of gut microorganisms [19,20]. Intestinal
NHE3 inhibition may also display some beneficial effects by
changes in the neurohumoral system. However, gut-restricted
NHE3 inhibition did not impact renin angiotensin aldosterone sys-
tem activation in spontaneously hypertensive rats [9,10].Downloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. CPharmacological intestinal NHE3 inhibition involves several
interesting pharmacological strategies and approaches to reduce
intestinal sodium absorption [21]. Generally, drugs are designed
to be rapidly absorbed to achieve therapeutic plasma levels, and
then be eliminated by multiple pathways. In contrast, oral admin-
istration of non-absorbable drugs minimize systemic exposure andhagen from ClinicalKey.com by Elsevier on July 09, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
6 B. Linz et al. / IJC Heart & Vasculature 28 (2020) 100534exert their therapeutic effects locally in the gastrointestinal tract.
Non-absorbable and therefore non-systemic drugs display less
off-target systemic effects and thereby less drug-drug interaction,
toxicity, or side-effects. In this light, oral administration of highly
selective non-absorbable NHE3-inhibitors reduces the intestinal
water and sodium absorption in the gut. These inhibitors specifi-
cally target the membrane-bound protein-fraction of the NHE3,
which is expressed on the cell surface of the gut epithelia.4.1. Limitation
Herein, we provide the first characterization of the effects of
intestinal inhibition of NHE3 in an obese hypertensive rat model
on atrial remodeling. We did not observe spontaneous AF episodes
and therefore focused on the electrophysiological and histological
characterization of left atrial remodeling processes only. Due to tis-
sue size of the small rat atria, we had to focus on histological anal-
ysis within this study. We used direct contact mapping to
determine local conduction disturbances in the atria, however
optical mapping was not performed. An electrophysiological study
in the ventricles was not performed, as we focused on the develop-
ment of an atrial arrhythmic substrate for AF. The identification of
the involved mechanisms, particularly the analysis of the gut
microbiome and its potential antiarrhythmic effect, warrants fur-
ther study. Additionally, SHR-ob express hypertension and obesity
for their genetic changes and some results from animal experi-
ments cannot be directly extrapolated to humans but can be used
to generate hypotheses for future research. The effect of SAR treat-
ment on atrial electrophysiology in normotensive rats with a
healthy phenotype is lacking in this study. However, that SAR
results in a dose-dependent increase in feces sodium concentration
and intestinal water excretion in normotensive rats has been
investigated elsewhere [9]. Future pre-clinical and clinical inter-
vention studies should also focus on a potential atrial antiarrhyth-
mic effect of low sodium diet.4.2. Conclusion
This study is the first to show, that pharmacological inhibition
of intestinal sodium absorption displays beneficial effects which
are normally expected from dietary interventions, which are often
difficult to achieve. Whether pharmacological lifestyle modifica-
tion by intestinal NHE3-inhibition as investigated in this study in
rats or other pharmacological dietary interventions helps to main-
tain sinus rhythm warrants further studies and future approaches
in humans.Funding
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